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Abstract 
The epidemic of HIV in Malawi started earlier than in most of southern Africa and at its peak 15% of all adults were infected 
with HIV. Malawi is a low-income country and the cost of putting all HIV-positive people in Malawi onto ART, expressed as a 
percentage of the gross domestic product, is the highest in the world.1 In spite of the scale of the epidemic and the cost of 
dealing with it, Malawi has made great progress and the effectiveness, availability and greatly reduced cost of potent anti-
retroviral therapy (ART) make it possible to contemplate ending the epidemic of HIV/AIDS in Malawi. Here we consider what 
would have happened without ART, the No ART counterfactual, the impact on the epidemic if the current level of roll-out of 
ART is maintained, the Current Programme, and the likely impact if coverage is further expanded making treatment available 
to everyone who is eligible under the 2013 guidelines of the World Health Organization, starting in 2015 and reaching full 
coverage by 2020, the Expanded Programme. 
 The Current Programme has had a substantial impact on the epidemic of HIV and the number of people dying of AIDS. 
The Expanded Programme has the potential to avert more infections, save more lives and, most importantly, end the epidemic. 
The annual cost of managing HIV will increase from about US$132 million in 2014 to about US$155 million in 2020 but will 
fall after that. If the Expanded Programme is implemented several key areas must be addressed. Testing services will need to 
be expanded and supported by mass testing campaigns, so as to diagnose people with HIV and enrol them in treatment and 
care as early as possible. A regular and uninterrupted supply of drugs will have to be assured. The quantity and quality of 
existing health staff will need to be strengthened. Community health workers will need to be mobilized and trained to 
encourage people to be tested and accept treatment, to monitor progress and to support people on treatment; this in turn will 
help to reduce stigma and discrimination, loss to follow up of people diagnosed with HIV, and improve adherence for those on 
treatment. 
  
Introduction 
The epidemic of HIV in Malawi started early. In 1987 HIV 
testing was done on workers on the South African gold 
mines in which correlations were made between their HIV 
status and their country of origin.4 The men in the study 
came from South Africa, Malawi, Lesotho, Mozambique, 
Swaziland and Botswana but notably not from Rhodesia, 
now Zimbabwe. The prevalence amongst mine-workers 
from Malawi was 4%, among those from all other 
countries, including South Africa, it was about 0.03%. IN 
response to this finding the South African Chamber of 
Mines stopped recruiting novices from Malawi5 and the 
number of Malawians employed on the South African 
mines fell from 13,090 in 1988 to 2,212 in 1989.6 These 
data are important for two reasons. First, they show that 
Malawi experienced the effects of HIV before most other 
countries in the region. Second, while excluding Malawian 
nationals from work on the mines will have seriously 
affected the economy of Malawi it may also, in the long 
run, have mitigated the impact of HIV. The spread of both 
HIV and TB in southern Africa is largely attributable to 
the system of oscillating migrant labour, introduced in the 
early 20th century to ensure a steady supply of cheap 
labour to the expanding gold mines while avoiding 
responsibility for the long term health of the workers.7 
This system of labour was expanded and entrenched under 
successive Apartheid governments and while the number 
of men employed in hard-rock mining has fallen 
substantially in the last 20 years, it still persists.  
 The key data on which this analysis is based are trends 
in the prevalence of HIV and of the coverage of anti-
retroviral therapy (ART) published by UNAIDS.2 These 
data suggest that the prevalence of HIV in Malawi peaked 
in 1998 and then continued to fall over the next five years, 
before ART became available in the public sector 
implying that there was a significant reduction in risky 
sexual activity at about that time. 
 In order to estimate the impact of early treatment on 
the epidemic of HIV we first consider a counterfactual in 
which we imagine that ART had never been made 
available in Malawi. We then compare this with what has 
happened and what will happen if the Current Programme 
of ART provision is continued and if an Accelerated 
Programme following the WHO 2013 guidelines8 is 
successfully implemented between now and 2020.  
 Here we fit the national trend in HIV prevalence to a 
dynamical model to estimate current and to project future, 
trends in prevalence, incidence, treatment needs and 
deaths. We estimate the per capita cost of HIV/AIDS, 
including the cost of providing drugs, providing support to 
people on ART, and hospitalization and access to primary 
health care facilities for people who are not on ART and 
develop AIDS related conditions. We do not include the 
social and economic costs incurred when people die of 
AIDS so that this calculation is conservative with regards 
to the overall cost to society. We have not allowed for 
population growth or discounted the costs. 
Data 
The ANC data for Malawi are sparse; in some years no 
data were collected, most facilities reported for only a few 
years, and there are few data on the early time course of 
the epidemic. The timing of the epidemic is important: the 
earlier the epidemic started the more people are likely to 
have advanced HIV-disease and vice versa. Here we use 
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the current UNAIDS estimates of the trend in the 
prevalence of HIV but it would be useful to review all 
available prevalence data to obtain the best possible 
estimate of the trend in the prevalence of HIV in Malawi. 
 Cost data are obtained from a study carried out by the 
Clinton Health Access Initiative (CHAI)9 and the key data 
are in Table 1.  
Table 1. Costs per person per year or per test for HIV 
tests, anti-retroviral drugs, laboratory running costs, 
care and support, and clinical care for those not on 
ART, in each of four WHO clinical stages. 
Item Cost (US$)
HIV test kit 14 
Carrying out one test 10 
Total 24 
First line drugs 66 
Second line drugs 483 
Average 73 
Personnel 29 
Laboratory 5 
Other 36 
Laboratory running costs 70 
Viral load test 20 
Medications and supplements 16 
Investments and other running costs 12 
Care and support  70 
Monitoring and support 118 
Clinical stage I  17 
Clinical stage II 33 
Clinical stage III 67 
Clinical stage IV 134 
Hospitalization (average) 63 
 
 An important cost relates to the cost and number of in- 
and out-patient days that people spend in clinics and 
hospitals if they are not provided with ART. Since these 
data are currently lacking for Malawi we use data from 
South Africa.10-12 The data for South Africa suggest that 
the medical cost, averaged over the life-time of a person 
infected with HIV, is about US$800 per year. Since the 
per capita spending on health in Malawi is 8.1% of that in 
South Africa13 we set the cost to US$63 per person per 
year, averaged over all four clinical stages, but allow it to 
double from each stage to the next (Table 1). 
Epidemic Model 
The model is a standard dynamical model discussed in 
detail elsewhere.14,15 It includes uninfected people who are 
susceptible to infection while infected people go through 
four stages of infection to death to match the known 
Weibull survival for people infected with HIV but not on 
ART.16 To account for heterogeneity in the risk of 
infection we let the transmission parameter decline with 
the prevalence of HIV following a Gaussian curve.14,15 
Table 2. The birth, background mortality and transition rates 
are fixed;14 the other parameters are varied to optimize the 
fit to the trend in the prevalence of HIV shown in Figure 1. 
Parameter Value 
Adult population in 2012 (millions)2 9.1 
Population growth rate (percent/yr)18 2.7 
Adult mortality (percent/yr)19 3.6 
Force of infection/yr 0.33 
Prevalence at which transmission is halved (%) 11.8 
Shape parameter17 2.25 
Transition rate/yr between HIV stages off ART 0.348 
Transition rate/yr between HIV stages on ART 0.087 
Fitting the model 
We first fit the model to the prevalence data without 
including ART to get the No ART counterfactual against 
which to compare the impact of ART. We vary the 
prevalence of infection in 1970, which determines the 
timing of the epidemic; the rate of increase; and the rate at 
which the risk of infection declines as the prevalence 
increases which determines the peak value of the 
prevalence. The fitted values are given in Table 2. Because 
of the decline in the estimated prevalence from 15% in 
1998 to 12% in 2007 we cannot fit the data unless we 
assume that there was a 50% reduction in the force of 
infection between 1999 and 2004. 
Table 3. Model parameters for logistic functions. Coverage 
gives the asymptotic coverage; Rate the exponential rate of 
increase; Half-max the year when coverage reaches half the 
maximum value. OR is the odds-ratio for the number tested to 
the prevalence of HIV in that stage. 
 Parameter Value 
 Asymptotic reduction 0.47 
Behaviour change Rate per annum 0.99 
 Half-min. year 2001.5 
Coverage 0.30 
Rate per annum 1.00 
Half-max. (year) 2006.3 
 
Passive case 
finding: Stage 4 
 OR (testing) 2 
Coverage 0.30 
Rate per annum 1.00 
Half-max. (year) 2011.1 
Passive case 
Finding: Stage 3 
 
OR (testing) 4 
Coverage 0.90 
Rate per annum 2.00 
Half-max. (year) 2016.0 
Test interval (yrs) 1.00 
Active case finding 
 
OR (testing) 10 
 To model the provision of ART in the Current 
Programme we assume that certain proportions of people 
in the third and fourth stages of HIV infection start ART 
and that coverage increases logistically. We then vary the 
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rate and timing of the increase and the proportion of 
people starting treatment in each stage to match the 
reported ART coverage (passive case finding in Table 3).  
 To model the Accelerated Programme we further 
increase the proportion of people starting treatment in all 
WHO clinical stages to between 50% and 80% and set the 
rate at which this roll-out happens to 1.0/year (Table 3) 
and we explore the effect of different levels of coverage. 
Testing rates and costs 
We assume that a proportion of HIV-positive people are 
tested a certain number of times each year and a 
proportion of those that test positive start ART. However, 
many people who are not infected will also be tested and  
 
in order to determine the cost of testing we need to know 
the case detection rate, that is the proportion of all those 
tested that are infected with HIV. Under passive case-
finding, people present to a health-service in Stages 3 or 4 
of HIV infection. We assume that of those that present to a 
health service with suspicions of HIV, 50% of those in 
Stage 4, 25% in stage 3 and 10% of those tested under 
active case finding, will be infected with HIV. Since we 
also have to avoid the mathematical possibility that we test 
more people than there are in the population we set the 
odds ratio for the number tested to the number that are 
HIV-positive to 2 for stage 4, 4 for stage 3, and 10 for 
active case-finding. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Top row: No ART. Middle row: Current Programme. Bottom row: Expanded Programme. Left: HIV prevalence. Blue: Data (with 
95% confidence limits) and fitted line. Red: not on ART. Green: Data for those on ART and fitted line. Orange: HIV incidence. Black: 
mortality not on ART. Brown: mortality on ART. Right: Cost. Brown: Drug costs; Orange: running costs; Green: Monitoring, care and 
support; Purple: medical care.  
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Results 
The fitted data and implied trends in prevalence, incidence 
and mortality as well as the number on treatment are shown 
in Figure 1 using the parameter values in Table 2 and Table 
3. Figure 1 gives the epidemiological projections on the left 
and the economic projections on the right. From top to 
bottom the graphs give the counterfactual under the No 
ART counterfactual, the Current Programme, and the 
Expanded Programme.   
No ART 
Figure 1A gives the prevalence of HIV (blue line and data), 
the implied incidence (orange line) and mortality (black 
line). Figure 1B gives the implied costs of in-patient and 
out-patient care10 (purple area). Prevalence rises rapidly, 
reaches a peak in 1999, declines equally rapidly for the next 
ten years, and then reaches a steady state at 9%. Incidence 
peaks in 1989 and declines as the epidemic saturates and 
people start to die. In 1998 the incidence starts to decline 
further as the force of infection falls, presumably due to 
changes in people’s behaviour, and levels off at about 0.8% 
per year. Mortality rises about ten years after the incidence, 
reflecting the mean life-expectancy of people with HIV, 
and also levels off at 0.8% per year. The annual cost to the 
health system (Figure 1B) as a result of having to treat 
people with AIDS related opportunistic infections increases 
to US$5.4 per adult per year, or US$49M per year, in 2000 
and then falls to a steady state at about US$3.5 per adult per 
year, or US$32M per year in total. 
Current programme 
The current programme has already achieved remarkable 
results. The number of people on ART has increased from 
close to zero in 2004 to about 364 thousand in 2012 (Figure 
1 C; green dots and line). This has reduced the incidence of 
infection in 2014 by 44% (Figure 1 A and C; orange lines) 
and reduced AIDS related deaths by 66% (Figure 1 A and 
C; black lines). The total cost of the epidemic to the country 
in 2014 has been increased from US$35 million to US$113 
million. Up to 2014 the Current Programme has saved 348 
thousand lives and prevented 157 thousand new infections 
at a cost of US$375 million (9.3 infections averted and 4.2 
lives saved per US$10 thousand spent). While the cost has 
been considerable the savings in new infections and lives 
have been very significant.  
Accelerated Programme 
The current (2013) guidelines of the International AIDS 
Society22 and the Department of Health and Human 
Services (DHHS)23 both recommend treatment for those 
infected with HIV, without regard to their CD4+ cell count, 
on the grounds that this is in the best interests of the 
individuals concerned and has the added benefit of reducing 
the likelihood that they will infect their partners. The 
current WHO guidelines are marginally more conservative 
recommending immediate treatment for everyone with a 
CD4+ cell count below 500/μL, those infected with TB, all 
pregnant women, all children under 5 years of age, as well 
as those with Hepatitis C and under these conditions an 
estimated 90% of people infected with HIV would be 
eligible to start ART as soon as they sero-convert. It would 
be remiss to go to great expense to avoid offering ART to 
the remaining 10% who would, in any event, be eligible for 
ART within one year. 
 Universal access to early treatment will reduce HIV 
transmission and AIDS related deaths to very low levels by 
2020 (Figure 1E, orange and black lines) but there will still 
be a very large number of HIV positive people on ART 
(Figure 1E: green line) who will have to be maintained on 
treatment for the rest of their lives. There will be an initial 
increase in costs as the backlog of untreated patients is 
taken up, the costs will reach a peak of about US$17 per 
adult or US$155M in total in 2020 but will fall rapidly after 
that (Figure 1F) as the prevalence of infection falls. Malawi 
currently spends US$74 per capita per year on health care 
so that at the peak expenditure ART would take up 23% of 
the total health care budget. 
Conclusion 
No ART 
The available data suggest that the adult prevalence of HIV 
in Malawi had already reached 0.9% in 1980, rose rapidly 
to a peak of 15% in 1998 but had declined to 12% in 2005, 
before ART became widely available in the public sector. 
This decline suggests that there was a significant reduction 
in sexual-risk behaviour between 1999 and 2004. If the 
reasons for this change can be understood and the change in 
behaviour reinforced this could help to strengthen 
prevention efforts to control the epidemic. Without the 
provision of ART and without further changes in behaviour, 
it is likely that the prevalence would have stabilized in the 
year 2000 at about 9.3%, the incidence and mortality at 
about 0.8%, so that there would have been about 74 
thousand new cases and deaths every year with associated 
health care costs of US$32 million to which one should add 
the social and economic costs of letting young adults die.  
Current programme 
In 2002 Malawi began an ambitious programme of ART. In 
2014 an estimated 9.7% of adults, or 884 thousand people, 
are infected with HIV but 4.5% of adults, or 410 thousand 
people, are receiving ART, can be expected to live a normal 
life and will not infect their partners. Compared to the No 
ART counter-factual the Current Programme has already 
saved 348 thousand lives and prevented 157 thousand new 
infections at a cost of US$375 million (9.3 infections 
averted and 4.2 lives saved per US$10 thousand).  If the 
current level of ART provision is maintained then, by 2050, 
this will have averted 1.6 million new infections in adults 
and saved 2.6 million lives at a cost of US$2.1 billion (7.6 
infections averted and 12.4 lives saved per US$10 
thousand). However, there will still be 255 thousand people 
infected with HIV, 73 thousand new infections and 9 
thousand AIDS deaths each year. 
Expanded Programme 
If Malawi embraces the 2013 WHO Guidelines for ART 
eligibility, then with 80% coverage and annual testing the 
Expanded Programme will, by 2020, further reduce the 
number of adults infected with HIV among adults not on 
ART to 50 thousand, the number of new infections to 6 
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thousand and AIDS deaths to 3 thousand. By 2025 the 
number of new infections and deaths will be in the 
hundreds per year and falling. By 2050 the Expanded 
Programme this will have averted a further 1.0 million new 
infections in adults and saved a further 360 thousand lives 
but it will also have saved Malawi US$260 million. 
Caveats 
This analysis is based on trends in the prevalence of HIV in 
adults derived from the Spectrum model.2 These data 
suggest that the force of infection in Malawi fell by about 
50% between 1999 and 2004. This alone will have reduced 
the case reproduction number from about3 4.4 to 2.2 so that 
a relatively low level of ART provision will have had a 
significant impact and a relatively low increase in the 
coverage of all infected people will end transmission. It is 
therefore of great importance to establish the nature and 
extent of this early decline in the prevalence of HIV. 
Bringing it all together 
Figure 2 compares the impact of the Current Programme 
and the potential impact of the Expanded Programme with 
the No ART counter factual.  
 The Current Programme has already averted 160 
thousand new infections and saved 348 thousand lives. 
While it will continue to avert new infections and save lives 
the epidemic will continue indefinitely. The Expanded 
Programme will avert even more infections and save even 
more lives although the impact on new infections, and 
therefore on transmission, will be particularly important. 
 Between now and 2050 the cost per life saved will be 
close to US$816 under the current programme and  US$632 
under the expanded programme while the expanded 
programme will have saved an extra 3.2 thousand lives and 
US$2.3 million. Furthermore, the cost of the Expanded 
Programme will break even in about 2045 and will be cost 
saving after that. 
Discussion 
Malawi has experienced a severe epidemic of HIV and, 
given that it is a relatively poor country by regional 
standards, the response to both HIV and TB has been 
admirable. The epidemic appears to be in decline as a result 
of significant changes in behaviour but also the successful 
roll out of ART. If the response can be further strengthened 
then it should be possible to end AIDS in Malawi. 
 It is important to bear in mind that this analysis depends 
on the apparent decline in the prevalence of HIV before 
ART became widely available and the validity of this 
observation deserves careful confirmation. It is of interest 
to note that the decline in prevalence appears to have 
happened at about the same time as it happened in 
Zimbabwe where the data to support this observation are 
much stronger.24 It is therefore possible that there was a 
significant shift in people’s behaviour at about that time. It 
may also be relevant to note that the South African mining 
industry did not recruit labour from Rhodesia, now 
Zimbabwe, except for a brief period in the 1970s and, as 
noted above, they ceased to recruit men from Malawi after 
1987. This exclusion from the system of oscillating migrant 
labour might have contributed to the decline in Malawi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. As compared to a counterfactual in which ART was not 
available the figure shows: A. Cumulative new infections averted; 
B. Cumulative lives saved; D. Cumulative costs. Red line: current 
programme; blue line expanded programme. 
 As in other countries in this region two critical issues 
are drug supply and adherence. A regular and reliable 
supply of drugs must be assured. Stock-outs will create 
anger and mistrust among infected people and poor 
adherence, for any reason, will lead to viral rebound, 
treatment failure, on-going transmission and drug 
resistance. The reported drop out rates of 23% at one year 
and 6% a year thereafter remain a cause for concern. These 
two considerations must be at the forefront of plans to 
effectively control and eventually eliminate HIV. Given the 
shortage of trained clinicians the programme will have to 
depend heavily on community mobilization and the training 
and support of a cadre of community health workers. 
However this will help to facilitate community 
involvement, empower local people and especially women, 
create jobs and stimulate local economies.  
 With currently available interventions universal access 
to early treatment is the only way to eliminate HIV in 
Malawi and all HIV-positive people will die of AIDS 
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related conditions if they do not start ART; starting as soon 
as possible after sero-conversion will give them their best 
prognosis. Other methods of support and control can and 
should play an important supporting role.25 To achieve high 
levels of compliance it will be necessary to deal with 
problems of stigma and discrimination and to ensure that 
there is strong community involvement and support for 
people living with HIV.   
 This paper focuses on treatment but continued scale-up 
of prevention interventions are critical to the HIV response. 
Condoms are highly effective if used properly and should 
be available to all that need them. Reducing the number of 
sexual partners and better control of other sexually 
transmitted infections are important in their own right and 
will contribute further to the control of HIV. Other 
prevention packages designed for key populations also need 
to be in place and can make an important contribution to 
stopping the epidemic of HIV; universal access to early 
treatment provides an ideal entry point for each of them. 
Finally, by developing programmes that are firmly based in 
local communities it will be possible to provide training 
and education while employing community outreach 
workers thereby creating jobs and stimulating local 
economies and ensuring sustainability. 
 It is still important to confirm the validity or otherwise 
of these results and to improve the model predictions. Here 
we have used the reported coverage of ART but this has 
never been directly measured. To do so, an appropriate 
sentinel surveillance system should be developed in order 
to carry out annual surveys on a reproducible and 
sufficiently large random and representative sample of 
adults. These surveys should include HIV testing and those 
that test positive for HIV should be tested for the presence 
of anti-retroviral drugs, their viral loads should be 
measured, and an incidence assay be used to estimate 
incidence. These would provide an important supplement to 
the important information already being collected and 
reported in the Quarterly Reports. 
 What is needed now is informed leadership and a 
further Expanded Programme of universal testing and 
immediate access to treatment, combined with good 
operational research, while monitoring the impact and 
implementation of the programme. The sooner that this is 
started the more lives and money that will be saved. 
Malawi has the wherewithal to stop the epidemic and the 
international community should support their commitment 
and determination to achieve an AIDS Free Generation. 
Appendix 1 
The World Health Organization guidelines26 of 2013 advise 
HIV-positive people to start ART if their CD4+ cell count 
is less than 500/μL, if they have TB or Hepatitis B, if they 
are pregnant, under the age of five years, or in a sero-
discordant relationship. Data on the distribution of CD4+ 
cell counts in HIV-negative people27 suggest that about 
80% of all those currently infected with HIV in South 
Africa and not on ART will have a CD4+ cell count below 
500/μL. If we include the other groups of people that 
should start treatment irrespective of their CD4+ cell count, 
then about 90% of all HIV positive people are currently 
eligible for ART. 
 If there is a need to triage people in order to treat those 
at greatest risk first, the sensible way to do this would be on 
the basis of their viral load. Individual CD4+ cell counts 
can vary by an order of magnitude within populations,27 the 
mean CD4+ cell count can vary by a factor of two between 
populations,27 and survival is independent of the initial 
CD4+ cell count.27,28 CD4+ cell counts therefore have very 
little prognostic value except in that unfortunate 
circumstance when the count is very low by which time an 
infected person is likely to be in WHO clinical stages III or 
IV and in need of immediate treatment anyway. 
Considerable savings in time, human resources and money 
could be had by abandoning the use of CD4+ cell counts 
for deciding on when to start ART. People with a high viral 
load, on the other hand, have a reduced life expectancy29 
and are more infectious than those with a low viral load.30 
If the availability of anti-retroviral drugs is limited it would 
therefore have the greatest benefit for individual patients 
and have the greatest impact on transmission if preference 
was given to people with high viral loads.31 
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